Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health (HIMS) disclosed an insider transaction by its Chief Legal Officer. On 10/13/2025, the officer sold 2,637 shares of Class A common stock at $54.38 per share (Transaction Code S) and held 161,130 shares directly after the sale. The sales were effected under a Rule 10b5-1 trading plan adopted on August 28, 2024.
Hims & Hers Health, Inc. notice reports a proposed sale of 900 Class A shares through Fidelity Brokerage Services LLC on 10/10/2025 with an aggregate market value of $52,425. The filer indicates the shares derive from an option granted on 08/10/2022 and show cash payment on the stated sale date. The filing lists recent insider sales by Michael Y. Chi totaling $4,240,268.50 across eight transactions between 07/23/2025 and 10/01/2025.
The notice includes the required representation that the seller does not possess undisclosed material adverse information and identifies this as a Rule 144 notice of proposed sale. No earnings, guidance, or other operational metrics are disclosed in this form.
Insider transactions on 10/03/2025: the Chief Financial Officer, Oluyemi Okupe, adopted a Rule 10b5-1 plan and executed option exercises and open-market sales. The reporting shows 11,595 shares sold at an average weighted price of $57.7173 (range $57.41–$58.09), and two option exercises: 7,787 options at an exercise price of $5.01 and 3,808 options at $11.53. Post-transaction holdings include reported direct ownership entries for Class A common stock and optioned shares underlying 182,165 and 59,976 share tallies respectively as disclosed. The Form states vesting schedules for the options and notes sales were made under the 10b5-1 plan.
Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported option exercise and an immediate sale under a pre-existing trading plan. On 10/01/2025 he exercised 250 stock options at an exercise price of $11.53 per share and sold 250 shares at $56.00 per share. After these transactions his reported beneficial ownership of Class A common stock was 291,439 shares and he holds 47,106 stock options outstanding. The Form 4 states the trades were made pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2025, and that the options vest monthly over a four-year service period beginning April 1, 2023.
Hims & Hers Health, Inc. reported that on September 28, 2025 its Chief Operating Officer, Nader Kabbani, will move to an advisory role effective November 2, 2025 and will provide strategic guidance through July 2026. The company will promote Mike Chi, currently Chief Commercial Officer, to Chief Operating Officer effective on the Transition Date and will eliminate the separate Chief Commercial Officer role, consolidating operations, marketing, product, and commercial functions under Mr. Chi. Mr. Chi joined the company in April 2021 and has over 20 years of consumer internet experience. Compensation review by the Compensation Committee is planned; any changes require final approval.
Form 144/A from Hims & Hers Health, Inc. (HIMS) reports a proposed sale of 154,958 common shares through Goldman Sachs & Co. LLC on 09/22/2025, with an aggregate market value of $9,161,116.96. The filing shows 217,641,958 shares outstanding. The securities to be sold were acquired mainly as compensation: multiple Restricted Stock Unit grants on 09/15/2025, 09/15/2024, 06/15/2024 and cashless exercises of stock options on 02/24/2022 and 03/01/2023. The filing also discloses sales by Oluyemi Okupe during the past three months totaling several transactions, including a 145,000-share sale on 09/15/2025 for $8,026,083.50. The notice includes the seller's representation that no undisclosed material adverse information is known.
Hims & Hers Health, Inc. Form 144 notice shows a proposed sale of 250 Class A shares through Fidelity Brokerage Services (NYSE) on 10/01/2025, with an aggregate market value of $14,000. The shares are reported as acquired on 10/01/2025 via options granted 03/01/2023 and will be paid in cash.
The filing also lists seven prior Class A sales by Michael Y. Chi during July–September 2025 totaling $3,717,768.50 in gross proceeds. The filer affirms no undisclosed material adverse information and provides broker and sale dates but omits filer CIK and full contact details in the provided text.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), executed option exercises and share sales under a Rule 10b5-1 plan on 09/29/2025. He exercised 49,832 stock options with a $5.01 exercise price and sold 85,000 Class A common shares at a weighted average price of $60.1991 (sales ranged $59.95–$60.48). Following the reported transactions, the filing shows 70,232 shares directly beneficially owned and 7,853 shares indirectly held by the Oluyemi Okupe Separate Property Trust dated 9-1-2021. The filing discloses remaining derivative holdings totaling 189,952 option shares following the transactions and notes vesting terms and the 10b5-1 plan adoption date of May 21, 2025.
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported an open-market sale of Class A common stock. On 09/29/2025 she disposed of 2,637 shares at $58.79 per share pursuant to a Rule 10b5-1 trading plan adopted August 28, 2024. After the sale she beneficially owned 163,767 shares, held directly. The Form 4 was filed by one reporting person and signed on behalf of the reporting person by an attorney-in-fact on 09/30/2025. The filing discloses no derivative transactions and provides no financial performance or forward-looking statements.
Hims & Hers Health, Inc. (HIMS) Form 144 notice reports a proposed sale of 2,637 Class A shares to be executed through Fidelity Brokerage Services on 09/29/2025 with an aggregate market value of $155,029.23, against 217,641,958 shares outstanding. The filing states those shares were acquired on 09/15/2025 by restricted stock vesting and were paid as compensation.
The filer discloses multiple recent Class A sales by Soleil Boughton during June–September 2025, each around 2,571–2,637 shares, generating gross proceeds reported per trade. The notice includes the standard Rule 144 representation regarding material nonpublic information and is a routine compliance filing for insider sales of vested compensation shares.